Article

Ablative Therapy for Barrett's Esophagus

The author of a study that compared the cost utility of ablation with that of endoscopic surveillance strategies explains his findings.

In this video from the American Gastroenterological Association, John M. Inadomi, MD, discusses the article "Ablative Therapy for Barretts Esophagus: A Cost-Utility Analysis.” The authors of the article compared the cost utility of ablation with that of endoscopic surveillance strategies. They concluded that endoscopic ablation “could be the preferred strategy for managing patients with Barrett's esophagus with high-grade dysplasia. Ablation might also be preferred in subjects with low-grade dysplasia or no dysplasia, but the cost effectiveness depends on the long-term effectiveness of ablation and whether surveillance endoscopy can be discontinued after successful ablation.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
© 2024 MJH Life Sciences

All rights reserved.